drugset / Trial / NCT07449156
A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.
Phase 1/2
Not yet recruiting
21 enrolled
Shanghai Huaota Biopharmaceutical Co., Ltd.
Dermatology Hospital affiliated to Shandong First Medical University · collab
RandomizedCrossoverSingle-blindTreatment
Summary
The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe AV.
Timeline
- Start
- 2026-03-27
- Primary completion
- 2026-10-27
- Completion
- 2027-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB0043 | Monoclonal antibody | 300 mg | Subcutaneous |